Insulet (NASDAQ:PODD) Given New $180.00 Price Target at Royal Bank Of Canada

Insulet (NASDAQ:PODD) had its target price boosted by stock analysts at Royal Bank Of Canada from $160.00 to $180.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada‘s price objective points to a potential upside of 16.45% from the company’s previous close.

PODD has been the subject of several other reports. Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Insulet in a research report on Wednesday. Wells Fargo & Company upped their target price on Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a research note on Thursday. Sanford C. Bernstein increased their target price on Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Wall Street Zen lowered Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. Thirteen research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insulet currently has an average rating of “Hold” and a consensus price target of $190.00.

Insulet Trading Down 6.3%

Shares of NASDAQ PODD traded down $10.45 during midday trading on Thursday, reaching $154.57. 738,488 shares of the stock were exchanged, compared to its average volume of 1,394,949. The company has a market capitalization of $10.72 billion, a P/E ratio of 28.86, a P/E/G ratio of 1.22 and a beta of 1.06. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $141.65 and a 200-day moving average price of $178.00.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company’s revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.24 earnings per share. Equities research analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Insulet during the second quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership raised its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc acquired a new position in Insulet during the second quarter valued at approximately $78,746,000. Bank of America Corp DE acquired a new position in Insulet during the second quarter valued at approximately $64,921,000. Finally, Bank of New York Mellon Corp purchased a new stake in Insulet during the second quarter worth approximately $60,615,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99 versus $1.59 expected and revenue of $842 million versus $832.6 million expected. Revenue grew 19.2% year over year, and reports noted margin expansion and a stronger 2026 outlook, though the full-year EPS outlook was maintained. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company announced a $1 billion share repurchase program, which may support per-share value and signal confidence in its business outlook. Insulet Announces $1 Billion Equity Buyback
• Positive Sentiment: Several firms raised their price targets: Bernstein to $200 with an Outperform rating, RBC to $180 with Outperform, and Wells Fargo to $172. RBC Raises Insulet Price Target
• Neutral Sentiment: UBS also lifted its target, to $171 from $150, but kept a Neutral rating—recognizing improved prospects without signaling a stronger recommendation. UBS Adjusts Insulet Price Target
• Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals taking some share from its Omnipod product. Those concerns may temper enthusiasm after the earnings beat and help explain why the stock is lower in Thursday trading. CEO Sees Slower Growth and Competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.